Leslie J. DeGroot MD (“Les”) was born on a dairy farm in Fort Edward NY in 1928, dedicated his life to thyroid disease research and endocrinology and died soon after his 90th birthday, on October 23, 2018 in Nonquitt, Massachusetts, surrounded by his many loving grandchildren, children and his wife.

This original article was published on October 2nd, 2018 in ConvergenceRI. PROVIDENCE, RI – The U.S. Food and Drug Administration announced on Tuesday, Oct. 2, that the federal agency has awarded EpiVax and CUBRC a $1 million contract over two years to establish best practices and procedures to evaluate generic peptide drugs for immunogenic potential and related ...

EpiVax has been awarded a $1 million contract from the Food and Drug Administration (FDA) to demonstrate and validate the best practices and procedures for assessing generic peptide drugs and related impurities for immunogenic potential.

NEW YORK CITY AND PROVIDENCE, RI., June 12, 2018 (BUSINESS WIRE) — EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced the closing of a $1.2M Bridge Financing. The investors include NextWaveBio, Morningside Venture Investments, Accelerate NY Seed Fund and Horatio Ventures NYC. EpiVax Oncology, Inc. (EO) is developing precision cancer immunotherapies based on Neo-Epitopes ...

PROVIDENCE, R.I., June 11, 2018 — EpiVax announces their move to a new headquarters at 188 Valley Street, in the “Rising Sun” complex, a former wool mill in the Olneyville section of Providence, Rhode Island. The privately held bioinformatics company is also celebrating its 20th anniversary. The mission of EpiVax is to “improve human health everywhere” through ...

PROVIDENCE, R.I., May 18, 2018 /PRNewswire/ — The National Institutes of Health (NIH) has awarded EpiVax, Inc. (“EpiVax”), experts in the field of immunogenicity risk assessment, a $324,980 Small Business Innovation Research (SBIR) grant. The funding will enable EpiVax to further develop the new Personalized Immunogenicity Assessment (PIMA) tool, for the individualized risk assessment of ...

PROVIDENCE, R.I., March 9, 2018 /PRNewswire/ — EpiVax Inc., (“EpiVax”) an innovative Rhode Island-based biotechnology company, has a lot to celebrate on International Women’s Day. The company, founded and led by Dr. Annie De Groot, boasts a female-majority work force and appears multiple times in the Providence Business News Book of Lists for Rhode Island: Top Private Companies (by revenue), Fastest ...

EpiVax Awarded Grant to Develop New Graves' Disease Therapy

EpiVax Oncology Press Release Sept 25 2017 Sept 25, 2017 (Providence, RI) – EpiVax, Inc., a leader in the fields of immunogenicity assessment, vaccine design, and immune-engineering today announced the launch of EpiVax Oncology Inc., a company focused on the development of personalized therapeutic cancer vaccines. EpiVax has provided $500,000 in seed funding and has provided ...

$5.8 MILLION AWARDED FOR VACCINE ENGINEERING WILL USE “IMMUNE HISTORY” TO PROTECT AGAINST BIRD FLU, A COLLABORATION LED BY EPIVAX   PROVIDENCE, R.I., Sept. 18, 2017– EpiVax, Inc. (“EpiVax”) a pioneer in the fields of bioinformatics and immune engineering, today announced a new NIH-funded collaboration to develop a protective avian influenza A (H7N9) vaccine. H7N9 is distantly related to seasonal influenza ...

EpiVax has carved out a niche in the biotech and immunoinformatics industry with our innovative tools and discoveries. Well-situated on a trajectory Dr. De Groot described as “upward and stable,” EpiVax is now gearing up to launch a venture-backed spinoff called EpiVax Oncology. EpiVax Oncology Inc. is a newly created, wholly owned subsidiary of EpiVax Inc. ...

EpiVax: Best Place to Work 2017!

Accelerating the Development of a Game Changing Cancer Therapy PROVIDENCE, R.I., Aug. 3, 2017 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) today announced it received funding from the Rhode Island Commerce Corporation to accelerate the development of personalized cancer vaccines using in silico methods. In partnership with Rhode Island Hospital, EpiVax’s innovative project aims to identify cancer-specific targets, or neoantigens, capable of directing ...

  A new article in Nature Scientific Reports (doi: 10.1038/s41598-017-01372-5) entitled A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines may explain why H7N9 influenza vaccines are consistently less immunogenic in humans than vaccines developed for other subtypes of influenza. In previous work, we identified a key T-cell epitope in H7 hemagglutinin (HA) that ...

Nineteen years ago, on May 18th, 1998, EpiVax incorporated as a biotechnology company. In 2017, our business has never been stronger: the team is stacked with talent, collaborations are abundant and world-wide, and our in silico user base is extensive. We were recently recognized as one of the 2017 Best Places to Work in Rhode Island, we are ...